首页>投融资

TRexBio

B轮

TRex Bio is a biotechnology company focused on the development of therapies for the potential treatment of immune-mediated diseases.In March 2022, the company completed a USD 26 million extension of its Series A financing in a round led by new investor Polaris Partners. This brings the total Series A funding raised to USD 85 million. Laurion Capital, and all the existing TRexBio institutional shareholders participated in the latest round including founding investor SV Health Investors, Eli Lilly, Johnson & Johnson Innovation JJDC, Pfizer Ventures and Alexandria Venture Investments.In June 2021, TRex Bio announced the closing of the final tranche of a $59 million Series A financing

https://trex.bio/

470178

基本信息

公司全称

TRex Bio Inc
类型

免疫疗法研发商
产业领域

药品研发/制造、医药研发/制造、化学药
公司人数

15~50人
地址

681 Gateway Blvd 4Th Floor SOUTH SAN FRANCISCO CALIFORNIA 94080; US;
联系电话

650-567-5582
邮箱

info@trex.bio
成立时间

2018-01-01

投融资

2024-11-13

B轮

8400万美元

Delos Capital

Avego Bioscience Capital

Agent Capital

Eli Lilly

SV Health Investors

辉瑞

Johnson & Johnson Innovation

Alexandria Venture Investments

Polaris Partners
2022-03-08

A轮

2600万美元

辉瑞

Alexandria Venture Investments

Johnson & Johnson Development Corporation

Polaris Partners

Laurion Capital Management

SV Health Investors

Eli Lilly
2021-06-22

A轮

5900万美元

Eli Lilly

Johnson & Johnson Innovation

Alexandria Venture Investments

辉瑞

SV Health Investors

TRexBio

基本信息

投融资

相关投融资企业